Sonoma Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

2. Liquidity and Financial Condition (Details Narrative) - USD ($)	6 Months Ended		8 Months Ended	12 Months Ended
	Oct. 04, 2018	Oct. 03, 2018	Nov. 21, 2018	Mar. 31, 2019	Mar. 31, 2018
Net loss				$ (11,798,000)	$ (14,328,000)
Accumulated deficit				(169,238,000)	(157,440,000)
Working capital				8,905,000	12,993,000
Proceeds from sale of equity, net				$ 4,743,000	$ 4,500,000
Public Offering [Member]
Proceeds from sale of equity, gross			$ 5,530,000
Proceeds from sale of equity, net			$ 4,743,000
Public Offering [Member] \| Common Stock [Member]
Stock issued new, shares			507,156
Public Offering [Member] \| Series C Preferred Stock [Member]
Stock issued new, shares			10
Public Offering [Member] \| Warrant [Member]
Stock issued new, shares			307,188
At Market Issuance Sales Agr [Member]
Stock issued new, shares	12,556			29,710	25,333
Proceeds from sale of equity, net				$ 957,000	$ 968,000
At Market Issuance Sales Agr [Member] \| Common Stock [Member]
Stock issued new, shares	12,556	29,710
Proceeds from sale of equity, gross	$ 270,000	$ 999,000
Proceeds from sale of equity, net	$ 262,000	$ 957,000